Jellinger K, Kothbauer P, Volc D, Vollmer R, Weiss R
Acta Neurochir (Wien). 1979;51(1-2):1-13. doi: 10.1007/BF01401790.
Postoperative survival time and recurrence-free intervals in 116 consecutive patients with supratentorial grade III and IV gliomas (glioblastomas, gliosarcomas, anaplastic astrocytomas, and ependymomas) were compared in unselected groups receiving different forms of treatment. Postoperative high-voltage radiotherapy (31 patients, dosage 4,000--6,000 rads) and combined chemotherapy consisting of CCNU, vincristine, amethopterine, and procarbazine in 15-day circles (COMP protocol) (12 patients) showed the same median survival time of 10.6 months and comparable recurrence-free intervals of 6.8 and 7.0 months, respectively. These results were significantly different from a control group (39 patients) receiving best postoperative supportive (conventional) care (median survival 5.4 months, free interval 3.7 months). Combination of postoperative radiotherapy with simultaneous polychemotherapy (COMP protocol), evaluated in 18 patients, did not significantly change the recurrence-free interval (median 7.0 months), but increased the median survival time to 12.9 months, which was significantly superior to the two other treatment groups. The toxic side effects of COMP therapy were moderate and essentially haematological. In general, simultaneous radiation and chemical treatment was well tolerated after major tumour resection. These preliminary results of postoperative combination of radiation and polychemotherapy for anaplastic supratentorial gliomas appear encouraging, but further trials for optimization of combined therapeutic strategies are warranted.
对116例幕上III级和IV级胶质瘤(胶质母细胞瘤、胶质肉瘤、间变性星形细胞瘤和室管膜瘤)连续患者,在接受不同治疗方式的未筛选组中比较术后生存时间和无复发生存期。术后高电压放疗(31例患者,剂量4000 - 6000拉德)和由CCNU、长春新碱、氨甲蝶呤和丙卡巴肼组成的联合化疗,每15天为一周期(COMP方案)(12例患者),显示中位生存时间相同,均为10.6个月,无复发生存期分别为6.8个月和7.0个月,具有可比性。这些结果与接受最佳术后支持(传统)治疗的对照组(39例患者)有显著差异(中位生存5.4个月,无复发生存期3.7个月)。对18例患者评估的术后放疗联合同步多药化疗(COMP方案),未显著改变无复发生存期(中位7.0个月),但将中位生存时间提高到12.9个月, 显著优于其他两个治疗组。COMP疗法的毒副作用中等,主要是血液学方面的。一般来说,在大肿瘤切除术后,同步放疗和化疗耐受性良好。幕上间变性胶质瘤术后放疗和多药化疗联合治疗的这些初步结果似乎令人鼓舞,但有必要进一步试验以优化联合治疗策略。